We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Reasons to Retain QuidelOrtho Stock in Your Portfolio for Now
Read MoreHide Full Article
QuidelOrtho Corporation (QDEL - Free Report) is well-poised for growth in the coming quarters, courtesy of its strong product portfolio. The optimism, led by a solid third-quarter fiscal 2024 performance and its continued spending on research and development (R&D), is expected to contribute further. However, risks due to overdependence on diagnostic tests and reimbursement policies persist.
This Zacks Rank #3 (Hold) company has lost 45.7% in the year-to-date period against 14.5% growth of the industry. The S&P 500 has witnessed 27.2% growth in the said time frame.
The renowned rapid diagnostic testing solutions provider has a market capitalization of $2.75 billion. QuidelOrtho’s earnings yield of 4.4% compares favorably with the industry’s 1.8%. The company’s earnings surpassed the Zacks Consensus Estimate in three of the trailing four quarters and missed the same in one, the average surprise being 50.28%.
Image Source: Zacks Investment Research
Factors Favoring QDEL’s Growth
Robust Product Portfolio: We are upbeat about QuidelOrtho’s current product clientele. It sells its products directly to end users and distributors for professional use in physician offices and hospitals, among others, as well as for individual, non-professional, over-the-counter use. QuidelOrtho’s diagnostic testing solutions include the Sofia and Sofia 2 Analyzers, QuickVue, InflammaDry and AdenoPlus products.
Per management, Savanna is continuing to provide significant competitive advantages in the Molecular Point-of-Care market. A successful U.S. launch of QDEL’s Savanna instrument is likely to offer incremental revenues and margin growth opportunities for the company. Building on the Savanna instrument and HSV panel approvals in the United States, the company expects to enter clinical trials on its respiratory panel later this year. The company aims to be in the market with both the Respiratory Panel and the STI panel in 2025.
In August 2024, QDEL announced the FDA 510(k) clearance for its VITROS syphilis assay as part of its menu, which is likely to strengthen its position as a leader in infectious disease testing. The company also announced the FDA 510(k) clearance for its QuickVue COVID-19 test. With CLIA certificates of waiver, this approval grants permission for the test to be used accurately and conveniently in home and medical healthcare settings.
In April 2024, QuidelOrtho announced the addition of the ARK Fentanyl II Assay to its U.S. Vitros XT 7600 and 5600 Integrated Systems, as well as its Vitros 4600 Chemistry System menu of assays as a MicroTip Partnership Assay. In March 2024, the company announced the receipt of Health Canada’s approval for its Triage PLGF (placental growth factor) test for laboratory use in Canada.
Continued Spend on R&D: QDEL’s long-term growth and profitability will mostly depend on its capacity to satisfy consumer requirements and expectations by creating and providing new, improved products and services that increase and draw in new clients. QuidelOrtho management expects to keep a strong focus on R&D expenditures for long-term growth, which will include new assays for its current platforms, as well as next-generation platforms and assays.
However, in the third quarter of fiscal 2024, research and development expenses declined 9.1% year over year to $55.9 million.
Strong Q3 Results: QuidelOrtho’s earnings and revenues beat the Zacks Consensus Estimate in the third quarter of 2024. The company witnessed growth in its recurring revenues. Strong revenue growth in the EMEA and Japan, Asia-Pacific and Latin America regions buoys optimism.
Per the third-quarter earnings call, the respiratory business performed well during the quarter, with a strong performance on the Sofia flu and COVID-19 combo tests.
Factors That May Offset the Gains for QDEL
Overdependence on Diagnostic Tests: A significant percentage of QuidelOrtho’s total revenues comes from a limited number of its product families. The company’s revenues can be highly concentrated over a few products, including certain respiratory products.
For September 2024 and September 2023, revenues related to respiratory products accounted for approximately 23% and 25% of the company’s total revenues, respectively, primarily driven by sales of COVID-19 products. The year-over-year decline was related to the lower respiratory season in 2023 compared with the prior year, particularly in COVID-19-related testing, which was down roughly $1 billion.
Third-Party Reimbursement Policies: The end-users of QuidelOrtho’s POC products are primarily physicians and other healthcare providers. In the United States, healthcare providers like hospitals and physicians who purchase diagnostic products generally rely on third-party payers (mainly private health insurance plans, federal Medicare and state Medicaid) to reimburse all or part of the cost of the procedure. QuidelOrtho’s products will be affected if physicians and other healthcare providers do not receive adequate reimbursement for the cost of the company’s products from their patients’ third-party payers.
Estimate Trend
QuidelOrtho is witnessing an upward estimate revision trend for 2024. In the past 30 days, the Zacks Consensus Estimate for its earnings has increased 3 cents to $1.78 per share.
The Zacks Consensus Estimate for the company’s fourth-quarter 2024 revenues is pegged at $702.3 million, indicating a 5.4% decline from the year-ago quarter’s reported number.
MASI’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 17.10%. Masimo’s shares have risen 37.2% year to date compared with the industry’s 6.7% growth.
AngioDynamics, carrying a Zacks Rank #2 (Buy) at present, has an estimated growth rate of 38.2% for 2025. ANGO’s earnings surpassed estimates in three of the trailing four quarters and missed once, delivering an average surprise of 31.71%.
AngioDynamics’ shares have lost 8.9% year to date against the industry’s 6.7% growth.
Globus Medical, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 12.7%. GMED’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 12.1%. Its shares have risen 56.5% year to date compared with the industry’s 6.7% growth.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Reasons to Retain QuidelOrtho Stock in Your Portfolio for Now
QuidelOrtho Corporation (QDEL - Free Report) is well-poised for growth in the coming quarters, courtesy of its strong product portfolio. The optimism, led by a solid third-quarter fiscal 2024 performance and its continued spending on research and development (R&D), is expected to contribute further. However, risks due to overdependence on diagnostic tests and reimbursement policies persist.
This Zacks Rank #3 (Hold) company has lost 45.7% in the year-to-date period against 14.5% growth of the industry. The S&P 500 has witnessed 27.2% growth in the said time frame.
The renowned rapid diagnostic testing solutions provider has a market capitalization of $2.75 billion. QuidelOrtho’s earnings yield of 4.4% compares favorably with the industry’s 1.8%. The company’s earnings surpassed the Zacks Consensus Estimate in three of the trailing four quarters and missed the same in one, the average surprise being 50.28%.
Image Source: Zacks Investment Research
Factors Favoring QDEL’s Growth
Robust Product Portfolio: We are upbeat about QuidelOrtho’s current product clientele. It sells its products directly to end users and distributors for professional use in physician offices and hospitals, among others, as well as for individual, non-professional, over-the-counter use. QuidelOrtho’s diagnostic testing solutions include the Sofia and Sofia 2 Analyzers, QuickVue, InflammaDry and AdenoPlus products.
Per management, Savanna is continuing to provide significant competitive advantages in the Molecular Point-of-Care market. A successful U.S. launch of QDEL’s Savanna instrument is likely to offer incremental revenues and margin growth opportunities for the company. Building on the Savanna instrument and HSV panel approvals in the United States, the company expects to enter clinical trials on its respiratory panel later this year. The company aims to be in the market with both the Respiratory Panel and the STI panel in 2025.
In August 2024, QDEL announced the FDA 510(k) clearance for its VITROS syphilis assay as part of its menu, which is likely to strengthen its position as a leader in infectious disease testing. The company also announced the FDA 510(k) clearance for its QuickVue COVID-19 test. With CLIA certificates of waiver, this approval grants permission for the test to be used accurately and conveniently in home and medical healthcare settings.
In April 2024, QuidelOrtho announced the addition of the ARK Fentanyl II Assay to its U.S. Vitros XT 7600 and 5600 Integrated Systems, as well as its Vitros 4600 Chemistry System menu of assays as a MicroTip Partnership Assay. In March 2024, the company announced the receipt of Health Canada’s approval for its Triage PLGF (placental growth factor) test for laboratory use in Canada.
Continued Spend on R&D: QDEL’s long-term growth and profitability will mostly depend on its capacity to satisfy consumer requirements and expectations by creating and providing new, improved products and services that increase and draw in new clients. QuidelOrtho management expects to keep a strong focus on R&D expenditures for long-term growth, which will include new assays for its current platforms, as well as next-generation platforms and assays.
However, in the third quarter of fiscal 2024, research and development expenses declined 9.1% year over year to $55.9 million.
Strong Q3 Results: QuidelOrtho’s earnings and revenues beat the Zacks Consensus Estimate in the third quarter of 2024. The company witnessed growth in its recurring revenues. Strong revenue growth in the EMEA and Japan, Asia-Pacific and Latin America regions buoys optimism.
Per the third-quarter earnings call, the respiratory business performed well during the quarter, with a strong performance on the Sofia flu and COVID-19 combo tests.
Factors That May Offset the Gains for QDEL
Overdependence on Diagnostic Tests: A significant percentage of QuidelOrtho’s total revenues comes from a limited number of its product families. The company’s revenues can be highly concentrated over a few products, including certain respiratory products.
For September 2024 and September 2023, revenues related to respiratory products accounted for approximately 23% and 25% of the company’s total revenues, respectively, primarily driven by sales of COVID-19 products. The year-over-year decline was related to the lower respiratory season in 2023 compared with the prior year, particularly in COVID-19-related testing, which was down roughly $1 billion.
Third-Party Reimbursement Policies: The end-users of QuidelOrtho’s POC products are primarily physicians and other healthcare providers. In the United States, healthcare providers like hospitals and physicians who purchase diagnostic products generally rely on third-party payers (mainly private health insurance plans, federal Medicare and state Medicaid) to reimburse all or part of the cost of the procedure. QuidelOrtho’s products will be affected if physicians and other healthcare providers do not receive adequate reimbursement for the cost of the company’s products from their patients’ third-party payers.
Estimate Trend
QuidelOrtho is witnessing an upward estimate revision trend for 2024. In the past 30 days, the Zacks Consensus Estimate for its earnings has increased 3 cents to $1.78 per share.
The Zacks Consensus Estimate for the company’s fourth-quarter 2024 revenues is pegged at $702.3 million, indicating a 5.4% decline from the year-ago quarter’s reported number.
Key Picks
Some better-ranked stocks from the medical industry are Masimo (MASI - Free Report) , AngioDynamics (ANGO - Free Report) and Globus Medical (GMED - Free Report) .
Masimo, sporting a Zacks Rank #1 (Strong Buy) at present, has an estimated growth rate of 10.4% for 2025. You can see the complete list of today’s Zacks #1 Rank stocks here.
MASI’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 17.10%. Masimo’s shares have risen 37.2% year to date compared with the industry’s 6.7% growth.
AngioDynamics, carrying a Zacks Rank #2 (Buy) at present, has an estimated growth rate of 38.2% for 2025. ANGO’s earnings surpassed estimates in three of the trailing four quarters and missed once, delivering an average surprise of 31.71%.
AngioDynamics’ shares have lost 8.9% year to date against the industry’s 6.7% growth.
Globus Medical, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 12.7%. GMED’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 12.1%. Its shares have risen 56.5% year to date compared with the industry’s 6.7% growth.